

Miami Breast Cancer CONFERENCE®

update

Use code:
MBCC18NEWS4
to save \$125!

A Message From the Chair

Patrick I. Borgen, MD

As 2018 begins, I find myself reflecting on what's happened in the past year. While 2017 certainly saw changes for all of us, I marvel at just how much has advanced in how we approach breast cancer, specifically.

In the time since the last **Miami Breast Cancer Conference®** we've seen the approval of novel agents designed to treat some of the most difficult forms of breast cancer and countless data on other agents that may soon be approved. Three new CDK4/6 inhibitors joined our armamentarium, traditional agents like fulvestrant were granted expanded indications, and piles of new data surrounding immunotherapies and therapies that target PARP or PI3K have changed the entire landscape of breast cancer treatment.

The **Miami Breast Cancer Conference®** is uniquely situated to cover the latest research findings, controversies, and breakthroughs of the past year. In Miami, our world-renowned faculty bring their unparalleled expertise to distill a year's worth of progress into an unrivaled educational program.

Whether it was first reported at a major meeting or the supplement of a journal, what you need to know, and how to use it, will be presented at Miami.

Join me in my New Year's resolution to better patient care—join me in Miami!

Sincerely,



Patrick I. Borgen, MD

Chairman, Department of Surgery
Maimonides Hospital
Director, Brooklyn Breast
Cancer Program
Brooklyn, NY



“HEAR IT ON FRIDAY....
....USE IT ON MONDAY.”

New Feature: Miami Breast Cancer Conference® Attendee Tumor Board

Miami Breast Cancer Conference® Attendee Tumor Board

Following 35 years of innovation and leadership, the **Miami Breast Cancer Conference®** revolutionized breast cancer education again this October, with our **Attendee Tumor Board**. This case-based, live-streamed interactive webcast was chaired by Patrick I. Borgen, MD, with featured discussions from Hope S. Rugo, MD and Miami Breast faculty Elizabeth A. Mittendorf, MD, PhD, and Debu Tripathy, MD.

Registration for the Attendee Tumor Board is included with **Miami Breast Cancer Conference®** registration.

Join us in Miami this March and maintain state-of-the-art care with us all year!

For more information visit us online now at...

gotoper.com/go/MBCC18NEWS4



New Approvals, New Indications

2017 saw the approval and expanded indication of 5 agents across treatment settings. Starting in March, **ribociclib**, a CDK4/6 inhibitor, was approved in combination with an AI to treat postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine therapy. Less than 3 weeks later, **palbociclib**, another CDK4/6 inhibitor, was approved under the same indication.

The summer continued at an accelerated pace, with the approval of neratinib, a TKI, for the extended adjuvant treatment of HER2-positive breast cancer, following treatment with trastuzumab. Then, in late August, **fulvestrant**, an estrogen receptor downregulator, was granted an expanded indication as a monotherapy for HR-positive, HER2-negative postmenopausal patients with no prior endocrine therapy. Wrapping up the approvals so far, **abemaciclib**, a third CDK4/6 inhibitor, was approved in combination with fulvestrant in the same setting as ribociclib and



A Year in Research

There's more to updates in breast cancer treatment than approvals alone. Groundbreaking research continues at a breakneck pace, incorporating novel agents and innovative strategies. From major meetings, to clinical reports, the future of breast cancer treatment starts in Miami. Highlighted below is just a small part of what happened this year.

Early last year, the AACR Annual Meeting highlighted that immunotherapy may have an expanded role in treating breast cancer. The PD-L1 inhibitor, **atezolizumab**, was shown to trigger a response in certain patients with TNBC. Abstracts at ASCO then showed the PD-1 inhibitor **pembrolizumab** had a significant response rate in patients with untreated TNBC.

The 2017 ASCO Annual Meeting brought us the first definitive data on the use of PARP inhibition in breast cancer. **Olaparib**, initially approved for ovarian cancer treatment in 2014, was shown to increase progression-free survival, when compared to chemotherapy, in the phase III OlympiAD trial.

Then, at the 2017 ESMO Congress, data from the phase II LORELEI trial showed the potential of PI3K inhibitor **taselisib** in the neoadjuvant setting, where it increased patients' overall response rate when used in combination with letrozole, compared with letrozole alone.

FEATURING | Miami Breast Mini-Symposium


The **Miami Breast Cancer Conference**® also offers attendees a unique Tumor Board-style **Mini-Symposium** the day before the official conference begins. The real world cases presented at the **Mini-Symposium** provide informative discussion on key challenges breast cancer specialists face in the clinic.

This year, the **Mini-Symposium** will take a more discussion-based, interactive approach. Cases will be presented to a panel of key opinion leaders, who will exchange multidiscipline perspectives and review relevant clinical evidence. This Tumor Board has been carefully designed to guide you through every phase of a patient's journey—from screening to diagnosis, from testing and first-line therapies, to treatment for metastatic disease. Participants will be able to weigh in on the most appropriate management options throughout this journey.

This special session has been specially developed to be of interest to all specialties, and provide practical information to enhance patient care. Come a day early, you won't want to miss this!



A YEAR IN BREAST CANCER



REGISTRATION

Use code: **MBCC18NEWS4** to save \$125!

First Name _____ Middle Initial _____
 Last Name _____ Degree(s) _____
 Physician Fellow PA-C NP Pharmacist Other _____
 Nursing license _____
 Are you employed by a for-profit organization, including biotech, financial, and pharmaceutical, defined as "Industry" by PER®?
 Yes No
 Address type: Home Hospital Office
 Mailing Address _____
 City _____ Prov/State _____
 Country _____ Postal/Zip Code _____
 E-mail (Your confirmation will be sent via e-mail) _____

Register now at
gotoper.com

	MINI-SYMPOSIUM + MAIN CONFERENCE March 08 - 11, 2018		MAIN CONFERENCE ONLY March 09 - 11, 2018	
	ADVANCE	ON-SITE	ADVANCE	ON-SITE
Physicians	\$1,169	\$1,289	\$829	\$879
Nurses, PAs, Other HCPs	\$979	\$1,099	\$639	\$689
Fellows**	\$979	\$1,099	\$639	\$689
Industry***	\$1,319	\$1,439	\$979	\$1029
Guest (access to receptions only)*	\$199	\$249	\$199	\$249

*FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount. Cannot be combined with other discounts/coupon codes.
 **INDUSTRY is defined by PER® as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.
 For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.
 A cancellation fee of 25% will be assessed on refunds requested through and including **January 28, 2018**, and a 50% fee on refunds requested on **January 29, 2018**, through **February 25, 2018**. No refunds will be made after **February 25, 2018**. There is no charge for substitution. Substitutions can only be applied to the same conference and only two substitutions will be honored.

Phone type: Home Mobile Work
 Phone _____ Fax _____
 Specialty _____ Birth Date (MM/DD/YYYY) _____
 Institute/Organization _____
 Payment can be made by: Check VISA MasterCard Discover American Express
 Charge Amount _____
 Card Number _____ Expiration Date _____
 Name as It Appears on Credit Card _____ Security Code _____
 Billing Address of Card (if different from above; zip code required) _____
 Signature _____

Practice Setting:

- Academic medical center/university
- Laboratory/basic research Pharmacy
- Community hospital-based practice
- Government agency
- Community office-based practice
- Pharmaceutical/biotechnology company
- In training (fellow, resident, student)
- Other

What is your principal activity?

- Patient care Clinical research
- Administrative Teaching/training Other

Preferred educational formats:

- Live Online Print

Preferred methods of communication:

- Phone Mail E-mail

Would you like to participate in CME surveys?

- Yes No

How many cancer patients do you treat each month? _____

Years practicing medicine _____

Would you like to enroll in the PER Point System?

- Yes No

Registration fees include continental breakfasts, breaks, receptions and e-syllabus materials.

All payments must be made by a draft on a United States bank.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

PER® complies with the Physician Payments Sunshine Act as part of the Affordable Care Act. Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the Act.

Accreditation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity has been approved for AMA PRA Category 1 Credit™.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669.

Miami Breast Cancer CONFERENCE *update*

2 Clarke Drive, Suite 110
Cranbury, NJ 08512

Phone: (888) 949-0045
E-mail: info@gotoper.com



Chairman



Patrick I. Borgen, MD
Chairman, Department of Surgery
Maimonides Hospital
Director, Brooklyn Breast Cancer
Program
Brooklyn, NY

Co-Chairs

Kimberly L. Blackwell, MD
Duke University Medical Center
Durham, NC

Elizabeth Mittendorf, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, TX

Debu Tripathy, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Register today and save \$125 off
the price of registration!
Use code: **MBCC18NEWS4**

For more information visit us online now at...

gotoper.com/go/MBCC18NEWS4

